FDA Greenlights Ocaliva and Zinbryta

Chronic liver disease candidate Ocaliva and the self-administered multiple sclerosis treatment Zinbryta both snagged FDA approval in late May.

Intercept Pharma’s Ocaliva earned accelerated approval for treatment of primary biliary cholangitis for use in conjunction with ursodeoxycholic acid in adults not responsive or intolerant to UDCA.

AbbVie and Biogen’s long-lasting multiple sclerosis injection Zinbryta scooped up FDA approval for monthly self-administration in patients with multiple relapsing forms of MS.